Does Semaglutide Cause You to Lose Muscle Along with Fat?
Research is split on whether semaglutide causes problematic muscle loss — some studies show the lean-to-fat ratio improves, while larger trials show significant lean mass reduction.
Quick Facts
What This Study Found
The evidence on semaglutide's impact on lean mass (muscle) is contradictory. Some studies show that while semaglutide causes decreases in both lean mass and fat mass, the ratio of lean mass to total body mass actually improves — meaning fat is lost proportionally faster than muscle. However, larger clinical trials have found significant reductions in lean mass, raising concerns about muscle loss.
This contradiction makes the real-world impact unclear: semaglutide users are definitely losing some muscle along with fat, but whether this represents a clinically meaningful problem — or simply the normal lean mass loss that accompanies any significant weight reduction — remains debated.
Key Numbers
Opinion paper synthesizing conflicting evidence · Lean-to-total body mass ratio may improve · Larger trials show significant lean mass reduction · No specific effect sizes reported
How They Did This
This is an opinion paper published in Clinical Nutrition that synthesizes and interprets existing research on semaglutide's effects on body composition, specifically lean mass. It discusses findings from multiple investigations and clinical trials to frame the current state of the debate.
Why This Research Matters
With millions of people now taking semaglutide for weight loss, the question of whether they're losing dangerous amounts of muscle is urgent. Muscle loss can lead to weakness, falls (especially in older adults), metabolic slowdown, and the characteristic "Ozempic face" and "Ozempic butt" that have drawn media attention. Understanding the true impact on lean mass is essential for guiding exercise recommendations, protein intake, and patient selection for GLP-1 therapy.
The Bigger Picture
The lean mass question has become one of the most important unresolved issues in GLP-1 medicine. It directly affects clinical guidance around exercise during treatment, protein intake recommendations, and whether resistance training should be considered essential rather than optional for GLP-1 users. It also intersects with the growing interest in combining GLP-1 drugs with myostatin inhibitors or other muscle-preserving agents to optimize body composition outcomes.
What This Study Doesn't Tell Us
As an opinion paper rather than a systematic review or meta-analysis, the evidence synthesis is selective rather than comprehensive. No specific effect sizes, percentages of lean mass loss, or trial-level data are reported in the abstract. The paper identifies the controversy but doesn't resolve it.
Questions This Raises
- ?Can resistance training fully prevent the lean mass loss associated with semaglutide, or is some loss inevitable?
- ?Is the lean mass loss from semaglutide different from that seen with equivalent weight loss from diet and exercise alone?
- ?Should older adults or those with sarcopenia be prescribed semaglutide differently to protect muscle mass?
Trust & Context
- Key Stat:
- Lean-to-total ratio may improve Despite absolute lean mass decreasing, some studies found the proportion of body mass that's muscle actually increases because fat is lost faster — complicating the narrative
- Evidence Grade:
- This is a preliminary-grade opinion paper that highlights conflicting evidence rather than providing definitive conclusions. While it synthesizes relevant research, it lacks systematic methodology and doesn't resolve the controversy.
- Study Age:
- Published in 2025, this is a very current paper reflecting the urgent debate around body composition changes in the millions of people now using GLP-1 drugs for weight loss.
- Original Title:
- Beyond fat: Does semaglutide affect lean mass?
- Published In:
- Clinical nutrition (Edinburgh, Scotland), 44, 104-108 (2025)
- Authors:
- Jamialahmadi, Tannaz(2), Eid, Ali H, Gadde, Kishore M(2), Almahmeed, Wael, Kroh, Matthew, Al Zein, Mohammad, Sahebkar, Amirhossein
- Database ID:
- RPEP-11565
Evidence Hierarchy
Frequently Asked Questions
Should I be worried about losing muscle on semaglutide?
Some muscle loss occurs with any significant weight loss, whether from drugs, surgery, or dieting. The key question — still being debated — is whether semaglutide causes more muscle loss than expected. Most doctors recommend resistance training and higher protein intake while on GLP-1 drugs as a precaution.
What does 'lean-to-total body mass ratio improves' actually mean?
It means even though you lose some muscle, you lose proportionally more fat. So if you started at 40% body fat and lost weight, you might end up at 35% body fat — your body composition improved even though absolute muscle mass went down. Whether this is acceptable depends on how much muscle was lost and your starting point.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11565APA
Jamialahmadi, Tannaz; Eid, Ali H; Gadde, Kishore M; Almahmeed, Wael; Kroh, Matthew; Al Zein, Mohammad; Sahebkar, Amirhossein. (2025). Beyond fat: Does semaglutide affect lean mass?. Clinical nutrition (Edinburgh, Scotland), 44, 104-108. https://doi.org/10.1016/j.clnu.2024.12.004
MLA
Jamialahmadi, Tannaz, et al. "Beyond fat: Does semaglutide affect lean mass?." Clinical nutrition (Edinburgh, 2025. https://doi.org/10.1016/j.clnu.2024.12.004
RethinkPeptides
RethinkPeptides Research Database. "Beyond fat: Does semaglutide affect lean mass?" RPEP-11565. Retrieved from https://rethinkpeptides.com/research/jamialahmadi-2025-beyond-fat-does-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.